Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04884282
Title Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Fondazione Ricerca Traslazionale
Age Groups: adult | senior
Covered Countries ITA

Additional content available in CKB BOOST